• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Angiol . The incidence and clinical impact of thrombotic events in hospitalised Coronavirus disease 2019 illness

tetano

Editor, Senior Moderator
Int Angiol


. 2022 Apr 4.
doi: 10.23736/S0392-9590.22.04845-3. Online ahead of print.
The incidence and clinical impact of thrombotic events in hospitalised Coronavirus disease 2019 illness


Bhupinder Singh[SUP] 1 [/SUP], Harmeet P Dhooria[SUP] 2 [/SUP], Bishav Mohan[SUP] 3 [/SUP], Abhishek Goyal[SUP] 3 [/SUP], Gurbhej Singh[SUP] 3 [/SUP], Parampratap Singh[SUP] 3 [/SUP], Mayur Goyal[SUP] 3 [/SUP], Suraj Luthra[SUP] 3 [/SUP], Shibba T Chhabra[SUP] 3 [/SUP], Rohit Tandon[SUP] 3 [/SUP], Naved Aslam[SUP] 3 [/SUP], Gurpreet S Wander[SUP] 3 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease-2019(COVID-19) infection and thrombosis are of great clinical importance as this association has shown to increase mortality. We intend to estimate the incidence of thrombotic events(TE) and their impact on clinical outcomes in hospitalised COVID-19 patients.
Methods: This was an analytical cross-sectional study. The study population comprised of hospitalised COVID-19 patients between 1st March 2021 and 31st May 2021. The clinico-demographic data, thrombotic events, and clinical outcomes were collected from electronic health records.
Results: A total of 1274 patients were analysed. The median age of the study population was 56 years (IQR:44-66 years). The estimated incidence of TE was 5.8%(n=74); 60.8% of these TE occurred in patients having severe/critical COVID-19 illness and 70.3% of TE occurred in patients in the intensive care unit. Venous events(3.9%) were common compared to arterial events(1.9%). On multivariate logistic regression analysis, total leukocyte count, C-reactive protein, and D-dimer level were found to be the independent predictors of having TE. Receiver operator curve revealed a cut-off point of 872.5 DDU μg/L for D-dimer level (sensitivity:67.6% and specificity:72.1%; p<0.001, area under curve=0.78) for predicting TE. Patients with TE had significantly higher mortality compared to those without TE (58.1% vs 22.2%; p<0.001); and the presence of TE (OR=2.94; 95% CI:1.7-5.1, p<0.001) was found to be the independent predictor of mortality.
Conclusions: The incidence of TE is high for hospitalised COVID-19 patients and it is even higher in severe/critical COVID illness. Its presence has shown to double the mortality compared to those without it.
 
Back
Top Bottom